Risk factors associated with fasting during Ramadan among individuals with diabetes according to IDF-DAR risk score in Atbara city, Sudan: Cross-sectional hospital-based study

Noor, Sufian K.; Alutol, Mo'min T.; FadAllah, FadAllahS.A.; Ahmed, Ahmed A.; Osman, Sohep A.; Badi, Safaa; Fathelrahman, Ahmed Ibrahim; Ahmed, Musaab; Ahmed, Mohamed H.

doi:10.1016/j.dsx.2023.102743

Cited by 5 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with diabetes who are at high or very high risk are recognized to be susceptible to hypoglycemia (especially during the day), undetected hyperglycemia (especially at night), dehydration, and DKA (especially at night) during the fasting period of Ramadan [14] . Hence, it is critical to choose an antidiabetic drug that is supported by scienti c data and does not typically induce hypoglycemia, which would need the patient to interrupt their fast [15] .…”

Section: Discussionmentioning

confidence: 99%

First-time Usage of SGLT2 Inhibitors in Patients with Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety

Abodahab,

Khalil,

Abdelal

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: Ramadan fasting claims a necessary role in management of diabetes. Many people with type 2 diabetes insist on fasting during the holy month of Ramadan, which represents a challenge to their physicians to provide balance between preventing hypoglycemia or diabetic ketoacidosis and good control of hyperglycemia with its short- and long-term complications. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a glucose-lowering therapy for type 2 diabetes which are generally well tolerated but may carry the risk of dehydration and hypoglycemia particularly during the long fasting hours. The study aimed to assess the efficacy and safety of the use of SGLT2i for the first-time during Ramadan fasting. Methods: This prospective cohort study was carried out on 61 Egyptian Muslim patients, aged ≥ 18 years old, both sexes, with type 2 diabetes mellitus (T2DM), prepared to fast during Ramadan and treated with SGLT2i for the first time as a supplementary to metformin or another oral hypoglycemic drug. The dose of SGLT2i started after Iftar time. During and Six weeks after Ramadan, evaluations were conducted. Results: Glycated hemoglobin (HbA1c), blood pressure (systolic and diastolic), and creatinine were significantly lower after Ramadan than at the beginning of Ramadan. The estimated glomerular filtration rate (eGFR) was significantly higher after Ramadan than at the beginning of Ramadan. Hypoglycemia, dehydration, and diabetic ketoacidosis (DKA) did not occur in any patient. There was a significant negative correlation between age and HbA1c (r=-0.267, P = 0.037) and eGFR (r =-0.684, P < 0.001) after Ramadan while there was no correlation between the duration of DM and HbA1c before and after Ramadan. HbA1c was significantly lower after Ramadan than during Ramadan in patients with ischemic heart disease (IHD), hypertension (HTN), peripheral neuropathy (PN), and chronic kidney disease (CKD) (P < 0.05). Conclusions: SGLT2i is effective and safe during Ramadan fasting with a significant reduction in HBA1c, blood pressure, and creatinine and a significant elevation of eGFR. Trial registration Clinical Trials giv ID: NCT06370247

show abstract

Section: Discussionmentioning

confidence: 99%

First-time Usage of SGLT2 Inhibitors in Patients with Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety

Abodahab,

Khalil,

Abdelal

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Several studies in 2023 evaluated the potential challenges and values of using the 2021 IDF-DAR (International Diabetes Federation-Diabetes and Ramadan Alliance) risk stratification tool (►Table 2). [14][15][16][17][18] The original creators of the tool investigated its validity using two different approaches. In the first study, they performed a prospective, survey-based study before and after Ramadan (2021) to explore the ability of the new IDF-DAR risk stratification tool to predict the probability of fasting and complications risk.…”

Section: Risk Stratificationmentioning

confidence: 99%

“…16,17 The first group assessed the scale using a cross-sectional hospital-based study that recruited 300 individuals with diabetes (79% have T2D) from diabetes centers in Sudan. 16 Risk scores were distributed as low risk (13.7%), moderate risk (24%), and high risk (62.3%). There was a significant difference in the mean risk score by sex, duration, and type of diabetes.…”

Section: Risk Stratificationmentioning

confidence: 99%

“…Two other groups from Sudan and Bangladesh evaluated the risk scale independently. 16 17 The first group assessed the scale using a cross-sectional hospital-based study that recruited 300 individuals with diabetes (79% have T2D) from diabetes centers in Sudan. 16 Risk scores were distributed as low risk (13.7%), moderate risk (24%), and high risk (62.3%).…”

Section: Highlights Of the Literaturementioning

confidence: 99%

Section: Highlights Of the Literaturementioning

confidence: 99%

See 2 more Smart Citations

Diabetes and Ramadan Fasting (2023): The Year in Review

Abusahmin,

Abdelgadir,

Eledrisi

et al. 2024

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

Introduction We aimed to provide an overview of the global literature production on diabetes and Ramadan in the past year (2023). Materials and Methods This is a narrative, nonsystematic review of the international literature from two major medical online databases (PubMed and Google Scholar) in 2023. The search term “Diabetes AND Ramadan fasting” was used, and the relevant literature was narrated in a concise thematic account. Results The publications spanned a vast array of topics related to diabetes and Ramadan fasting (RF), including physiology and nutrition, risk assessment stratification tools and their validation, assessments of safety and efficacy profiles of older and newer diabetes therapies, diabetes education, use of advanced technology for the treatment, and monitoring and impact on pregnancy. Some reports covered the interaction between Ramadan and COVID-19 concerning diabetes, pregnancy, complications, and unique characteristics of diabetes and fasting by young and older people. Conclusion The current narration presents this year's global scholarly production on the safety of fasting practices, care models, and patients' experiences and perspectives.

show abstract

Glucometric parameter changes in patients with type 2 diabetes during ramadan fasting: A prospective comparative real-world study

Al Hayek,

Al Zahrani,

Al Dawish

2024

Metabolism Open

View full text Add to dashboard Cite

Risk factors associated with fasting during Ramadan among individuals with diabetes according to IDF-DAR risk score in Atbara city, Sudan: Cross-sectional hospital-based study

Cited by 5 publications

References 29 publications

First-time Usage of SGLT2 Inhibitors in Patients with Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety

First-time Usage of SGLT2 Inhibitors in Patients with Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety

Diabetes and Ramadan Fasting (2023): The Year in Review

Glucometric parameter changes in patients with type 2 diabetes during ramadan fasting: A prospective comparative real-world study

Contact Info

Product

Resources

About